Influential factor and trend of specific IgG antibody titer in coronavirus disease 2019 convalescents.
10.11817/j.issn.1672-7347.2020.200421
- Author:
Chenggao WU
1
;
Wei LIU
2
;
Guoliang LI
2
;
Zhanglin ZHANG
2
;
Kun XIAO
2
;
Aiping LE
3
Author Information
1. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006, China. wuchenggao_21@126.com.
2. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
3. Department of Blood Transfusion, First Affiliated Hospital of Nanchang University, Nanchang 330006, China. leaiping@126.com.
- Publication Type:Journal Article
- Keywords:
IgG antibody;
antibody titer;
convalescent plasma;
coronavirus disease 2019
- MeSH:
Antibodies, Viral;
Betacoronavirus;
COVID-19/therapy*;
Female;
Humans;
Immunization, Passive;
Immunoglobulin G;
Male;
Pandemics;
Pneumonia, Viral/epidemiology*;
SARS-CoV-2
- From:
Journal of Central South University(Medical Sciences)
2020;45(10):1172-1175
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To explore the influential factors and titer trend of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific IgG antibody in convalescent patients with coronavirus disease 2019 (COVID-19), and to provide theoretical basis for the feasibility of clinical treatment of convalescent plasma.
METHODS:Colloidal gold immunochromatography assay was used to detect the SARS-CoV-2 specific IgG antibody and its titer in 113 convalescent patients with COVID-19 who were followed up from February 19, 2020 to April 6, 2020. The basic characteristics and treatment factors of patients in the high titer group (antibody titer≥1꞉160,
RESULTS:The difference in the clinical type of COVID-19, onset time, first admission C-reactive protein, absolute value of lymphocyte, absolute value of CD19
CONCLUSIONS:Male COVID-19 patients might be more likely to produce high titer SARS-CoV-2 specific IgG antibodies than female. The peak level of SARS-CoV-2 specific IgG antibody in convalescent patients is maintained for a short period. Using plasma from convalescent COVID-19 patients for treatment should be within 28 d after discharge.
